Innovation Pharmaceuticals announces dosing of first cohort in Crohn's treatment
Innovation Pharmaceuticals announces that the company has dosed the first cohort in its Phase 1 trial to investigate the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers. This study formally launches the company's clinical program in Ulcerative Colitis. Assessments will include the safety, toleration, and pharmacokinetics of oral Brilacidin, and whether the drug is being dispersed directly in the colon, as assessed by gamma scintigraphy. Dosing of all cohorts in the Phase 1 trial is expected to be completed within several weeks, and topline data to follow shortly. The start of this Phase 1 trial is a major milestone for the Company, a key part of its broader clinical program in Inflammatory Bowel Diseases, IBD, The study's primary objective is to show that Brilacidin can be delivered orally and selectively to the colon. This will enable the company to treat more extensive forms of GI disease, primarily Ulcerative Colitis and Crohn's Disease. Topline Results Anticipated Early Q1 2020.